GSK Bio
NEWS
GlaxoSmithKline shares jumped in aftermarket trading Wednesday after the WHO recommended broad deployment of the company’s malaria vaccine in sub-Saharan Africa and other areas.
With the planned departure from its 561,652-square-foot RTP campus, GSK will reduce its geographical footprint, but not its staff.
The deal’s termination was announced Thursday, months after bintrafusp alfa failed to hit the mark in a Phase II clinical trial as a potential second-line treatment for metastatic biliary tract cancer.
GlaxoSmithKline Chief Executive Officer Emma Walmsley faces renewed calls for her ouster after Bluebell Capital Partners has taken a £10 million (about $13.7 million) stake in the company.
CureVac NV is downsizing its European mRNA production network due to decreased demand for vaccines after the first wave of vaccinations.
AI can enable the analysis of massive databases, accelerate research and development, save costs and promote effective decision making.
The trial will enroll about 4,000 people worldwide to confirm the drug’s safety and immunogenicity profiles.
The research underlines the progress being made in messenger RNA approaches, as spotlighted by the success of the mRNA vaccines against COVID-19.
Biopharma companies and life sciences organizations strengthen their leadership teams and boards with these Movers & Shakers.
JOBS
IN THE PRESS